Created with Sketch.
13 minutes | Dec 6, 2022
Hemolytic Disease of the Fetus and Newborn (HDFN): What Pediatric Providers Need to Know When Managing Hemolytic Disease in Newborns (HDN)
CME credits: 0.25 Valid until: 06-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/hemolytic-disease-of-the-fetus-and-newborn-hdfn-what-pediatric-providers-need-to-know-when-managing-hemolytic-disease-in-newborns-hdn/13799/ What are the essential steps in managing hemolytic disease of the fetus and newborn (HDFN)? How soon after “the cord has been cut” does newborn care transfer from the maternal-fetal medicine specialist and ob-gyn to the pediatric team? At a recent satellite symposium of the American Academy of Pediatrics, Dr. James Bussel, Dr. Kara Markham, and Bethany Weathersby presented the latest data regarding current and emerging practice patterns and highlighted the critical need for improved understanding and multidisciplinary collaboration in the area of HDFN. Tune in to hear Dr. Markham summarize how diagnosis, care, and treatment have evolved—plus insights on how these might change the way you practice.
22 minutes | Dec 1, 2022
Osteoporosis: The Pivotal Role That Orthopedic Surgeons Can Play in Optimizing the Bone Health of Their Postmenopausal Post-Fracture Patients
CME credits: 0.25 Valid until: 01-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/osteoporosis-pivotal-role-orthopedic-surgeons-can-play-optimizing-bone-health-their-postmenopausal-post-fracture-patients/12949/ Since the recording of this CME activity, the following updates have been published: NAMS Position Statement on the Management of Osteoporosis in Postmenopausal Women Menopause. 2021;28(9):973-997. Consensus Statement from the Bone Health and Osteoporosis Foundation, formerly known as the National Osteoporosis Foundation The Clinician’s Guide to Prevention and Treatment of Osteoporosis. Osteoporosis Int. 2022;33(10):2049-2102. While there’s growing awareness among orthopedic surgeons that osteoporosis is the underlying cause of fractures, there is often a disconnect between this recognition and action in the form of treatment to prevent subsequent fractures. In this discussion, Drs. Andrea Singer, Paul Anderson, and Susan Bukata address the pathophysiology of osteoporosis and the need to identify patients at risk for additional fractures. Osteoporosis treatment (including pharmacotherapy) can play a critical role in preventing future fractures, but physicians must first recognize that fracture is a sentinel event and treat it as a call to action.
19 minutes | Nov 30, 2022
Innovations in the Treatment of Locally Advanced Squamous Cell Carcinoma of Head and Neck: Enhancing Antitumor Activity Through Inhibitor of Apoptosis Protein Antagonism
CME credits: 0.25 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/innovations-in-the-treatment-of-locally-advanced-squamous-cell-carcinoma-of-head-and-neck-enhancing-antitumor-activity-through-inhibitor-of-apoptosis-protein-antagonism/14129/ There is an unmet clinical need for more durable responses in many patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Advances in delineating the anti-apoptotic signaling mechanisms are guiding the development of novel therapeutic options for these patients. Join Drs. Kevin Harrington, Barbara Burtness, and Ari Rosenberg as they discuss challenges in treating patients with LA SCCHN and focus on the latest clinical data surrounding an antagonist of inhibitor of apoptosis proteins in this patient population.
31 minutes | Nov 30, 2022
Optimizing Care for Patients with Advanced Hepatocellular Carcinoma: Current Standards and Future Directions with Immunotherapy
CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-care-for-patients-with-advanced-hepatocellular-carcinoma-current-standards-and-future-directions-with-immunotherapy/14482/ Combination immunotherapy (IO) is revolutionizing the management of advanced hepatocellular carcinoma (HCC). Listen in as Dr. Richard Finn and Dr. Peter Galle break down the most recent data around emerging strategies for using IO to treat your patients with HCC. What impact will these advances have on your clinical practice?
31 minutes | Nov 30, 2022
Fatty Liver or NASH: The Future of Noninvasive Diagnosis and Assessment
CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/fatty-liver-or-nash-the-future-of-noninvasive-diagnosis-and-assessment/13651/ The use of noninvasive tools in NAFLD/NASH has become more prevalent over the last several years, with increased availability of imaging and serum-based tools. A forum of experts convened to discuss optimal use of these tools in NAFLD/NASH using a series of clinical assertion statements. These statements covered screening patients with diabetes, applicability of liver enzymes in determining fibrosis stage, use of transient elastography and blood-based tools, such as the Enhanced Liver Fibrosis test, and potential genetic testing. Here, Drs Jacobson and Younossi summarize the research and discussion points from the forum.
23 minutes | Nov 30, 2022
Establishing the Role of Immunotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) Endometrial Cancer
CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/establishing-the-role-of-immunotherapy-in-microsatellite-instability-high-msi-h-or-mismatch-repair-deficient-dmmr-endometrial-cancer/14459/ Are you testing for MSI-H/dMMR in your patients with advanced endometrial cancer? Listen in as Drs. Robert Coleman, Susana Campos, and Ana Oaknin break down the progress being made in biomarker testing and immunotherapy treatment for these patients.
21 minutes | Nov 30, 2022
Employing Immunotherapy and ADCs in Advanced Endometrial and Cervical Cancers: Current and Emerging Therapies
CME credits: 0.50 Valid until: 30-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/employing-immunotherapy-and-adcs-in-advanced-endometrial-and-cervical-cancers-current-and-emerging-therapies/14460/ The recent addition of immunotherapy to our armamentarium for endometrial and cervical cancer has shifted the treatment landscape. Listen in as Drs. Robert Coleman, Susana Campos, and Domenica Lorusso discuss innovations in immunotherapy and what role antibody-drug conjugates (ADCs) play in this setting.
19 minutes | Nov 23, 2022
Alloimmune Thrombocytopenia in the Fetus and Newborn
CME credits: 0.25 Valid until: 23-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/alloimmune-thrombocytopenia-in-the-fetus-and-newborn/13909/ Program Chairman:Roberto Romero, MD, DMedSciChief, Perinatology Research BranchDivision of Maternal-Fetal Medicine and ObstetricsDivision of Intramural ResearchNICHD/NIH/DHHSEditor-in-Chief for ObstetricsThe American Journal of Obstetrics and Gynecology As the platelet equivalent of hemolytic disease of the fetus and newborn, fetal and neonatal alloimmune thrombocytopenia (FNAIT) is an uncommon yet complex and life-threatening bleeding disorder that results from incompatibility between mother and baby for platelet-specific antigens. Despite relatively normal platelet function, in the setting of severe thrombocytopenia, intracranial hemorrhage is a consequence. Drs. Shulman and Bussel discuss advances in management strategies and concrete steps you can take to lower the risk and stop the progression of this disorder in your patients.
16 minutes | Nov 22, 2022
Medical Management of Uterine Fibroids: GnRH Antagonists
CME credits: 0.25 Valid until: 22-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/medical-management-of-uterine-fibroids-gnrh-antagonists/14144/ GnRH antagonists are revolutionizing the medical management of uterine fibroids. Drs. Al-Hendy and Shulman discuss how medical myomectomy with GnRH antagonists is revolutionizing care by bridging gaps during 3 different stages of patients’ lives.
10 minutes | Nov 21, 2022
Emerging Evidence in Second-Line and Potential Considerations in First-Line aGC and GEJ cancers
CME credits: 0.25 Valid until: 21-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/emerging-evidence-in-second-line-and-potential-considerations-in-first-line-agc-and-gej-cancers/14038/ HER2 is an essential biomarker to be assessed in all patients with gastric/GEJ cancer. Its importance is not only related to its role as a therapeutic target for pathway inhibition, but also to its ability to anchor the application of non-HER2 pathway therapeutic strategies with direct and bystander impact in the tumor microenvironment. Join Drs. Janjigian and Klempner as they delve into historical and exciting emerging data that may well bring new hope to your patients with gastric/GEJ cancers.
13 minutes | Nov 18, 2022
Direct from the Heart Failure Clinic: Novel Device Therapy for Patients with HFrEF
CME credits: 0.25 Valid until: 18-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/direct-from-the-heart-failure-clinic-novel-device-therapy-for-patients-with-hfref/14473/ Despite the use of guideline-directed medical therapy (GDMT), many heart failure (HF) patients may experience worsening symptoms and disease progression. There is now an FDA-approved device that works with GDMT and uses the baroreflex to improve HF-related physiological effects and clinical consequences. Tune in to keep up with baroreflex activation therapy, its mechanism of action, and the associated improved patient outcomes.
16 minutes | Nov 16, 2022
The Critical Role of Addressing Patient Fertility Desire in the Treatment of Uterine Fibroids and Endometriosis
CME credits: 0.25 Valid until: 16-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-critical-role-of-addressing-patient-fertility-desire-in-the-treatment-of-uterine-fibroids-and-endometriosis/14143/ Fertility preservation is a significant clinical concern for all women of reproductive age diagnosed with endometriosis or uterine fibroids (UF). Drs. Elizabeth Stewart and Lee Shulman discuss how the advent of GnRH antagonists is affecting how we approach these 2 conditions. Management trends are evolving beyond reflexive, prophylactic surgery, so are you ready to change with the times?
24 minutes | Nov 15, 2022
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
CME credits: 0.50 Valid until: 15-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/trop2-adcs-for-metastatic-nsclc-setting-the-stage-for-future-use/14416/ Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
29 minutes | Nov 15, 2022
Immune-Based Advances in Gastric, Esophageal, and Gastroesophageal Junction Cancers
CME credits: 0.50 Valid until: 15-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/immune-based-advances-in-gastric-esophageal-and-gastroesophageal-junction-cancers/14481/ Recent immunotherapy approvals for gastric, esophageal, and gastroesophageal junction cancers have transformed the treatment landscape. Listen in as Drs. Eric Van Cutsem, Elizabeth Smyth, and Sunnie Kim discuss the most recent data for immunotherapy in these settings. What impact will these advances have on your clinical practice?
17 minutes | Nov 11, 2022
Personalizing Treatment in Cushing’s Disease
CME credits: 0.25 Valid until: 11-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-treatment-in-cushings-disease/14397/ Cushing’s disease is complex, and individualized approaches require the consideration of many patient factors. You and your patient also need to know what to expect in terms of therapeutic response and speed of recovery. Tune in as Drs. Maria Fleseriu and Irina Bancos address these challenges and more!
26 minutes | Nov 4, 2022
Advances in the Care of Patients with MSI-H/dMMR or HER2+ Colorectal Cancers
CME credits: 0.50 Valid until: 04-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/advances-in-the-care-of-patients-with-msi-hdmmr-or-her2-colorectal-cancers/14480/ In this chapterized panel discussion, Drs. Aparna Parikh, Dustin Deming, and Scott Kopetz take us through NCCN recommended guidelines and best practices for identifying biomarkers. Armed with this knowledge, you’ll be able to select systemic therapies more accurately for your patients with MSI-high disease, as well as patients with HER2-amplified CRC.
13 minutes | Nov 2, 2022
Evaluating Your Current Options in the Treatment of NSCLC with METex14 Skipping Mutations
CME credits: 0.25 Valid until: 02-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/evaluating-your-current-options-in-the-treatment-of-nsclc-with-metex14-skipping-mutations/14089/ Take a deep dive into current and ongoing clinical trials related to MET inhibitors and discover the key distinctions between these agents, such as dosing differences. Our experts also have recommendations on appropriate therapy selection for your patients with advanced NSCLC harboring MET exon 14 skipping mutations.
11 minutes | Nov 2, 2022
Patient-Centered Discussions and Shared Decision-Making in the Management of NSCLC with METex14 Skipping Mutations
CME credits: 0.25 Valid until: 02-11-2023 Claim your CME credit at https://reachmd.com/programs/cme/patient-centered-discussions-and-shared-decision-making-in-the-management-of-nsclc-with-metex14-skipping-mutations/14088/ Join us as Dr. Jyoti Patel illustrates her approach to treating a 75-year-old patient who was recently diagnosed with stage IV NSCLC harboring a MET exon 14 skipping mutation—then put these tips to use in your own practice!
38 minutes | Nov 1, 2022
Menopause Matters…Let’s Start Paying Attention to Racial and Ethnic Differences: Current and Emerging Treatment Approaches
CME credits: 0.50 Valid until: 30-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/menopause-matterslets-start-paying-attention-to-racial-and-ethnic-differences-current-and-emerging-treatment-approaches/14519/ This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion. Current and Emerging Treatment ApproachesDr. Kagan and Dr. Kapoor discuss available and emerging hormonal and nonhormonal approaches to managing vasomotor symptoms.
31 minutes | Nov 1, 2022
Menopause Matters…Let’s Start Paying Attention to Racial and Ethnic Differences: Addressing Patient Needs
CME credits: 0.50 Valid until: 30-03-2023 Claim your CME credit at https://reachmd.com/programs/cme/menopause-matterslets-start-paying-attention-to-racial-and-ethnic-differences-addressing-patient-needs/14520/ This activity addresses disparities in the treatment of vasomotor symptoms faced by menopausal women of diverse racial and ethnic backgrounds. Faculty discussion covers overcoming these disparities, guideline recommendations, a novel mechanism for controlling vasomotor symptoms, and strategies to educate patients. First-hand patient testimonials complement the discussion. Addressing Patient NeedsThe faculty panel discusses the selection of therapy to meet unmet clinical needs across diverse women facing the menopause transition.
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2022